GLUT1‐Targeting and GSH‐Responsive DOX/L61 Nanodrug Particles for Enhancing MDR Breast Cancer Therapy

Abstract

AbstractEfficient targeting to tumor tissues and subsequent rapid drug release in cancer cells remains a major challenge for nanodrug delivery systems. Herein, smart nanodrug particles with reduction‐sensitive and active tumor‐targeting ability are constructed based on the nanoprecipitation of glucosamine‐grafted pluronic L61 (GA‐L61) and disulphide‐linked doxorubicin dimer (DOXSSDOX) to overcome tumor multidrug resistance (MDR). These nanoparticles show proper size and excellent stability under neutral conditions, while quickly release DOX due to the breakage of disulfide bonds under reductive medium. In vitro cellular uptake and drug efflux demonstrate that L61 can efficiently increase DOX concentration in MCF/ADR resistant cells by inhibiting the function of drug resistance proteins. In vivo biodistribution reveals that glucose transporter 1 (GLUT1)‐mediated tumor‐targeting significantly improves tumor accumulation of the glucosamine‐contained nanoparticles. Finally, the combination of GLUT1‐targeting, glutathione (GSH)‐responsive, and MDR‐reversal effects in nanoparticles achieve superior antitumor effects, which can provide an efficient, safe, and economic approach for drug delivery and cancer chemotherapy.